CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
MWN-AI** Summary
CytomX Therapeutics, Inc. has appointed Rachael Lester as Chief Business Officer, a strategic move aimed at enhancing the company’s business development efforts as it advances its oncology-focused initiatives. Based in South San Francisco, CytomX is recognized for its innovative PROBODY® therapeutic platform, which focuses on conditionally activated biologics aimed at delivering targeted cancer treatments. In her new role, Lester will be responsible for shaping the company's strategy and driving partnerships, an essential task as CytomX aims to expand its clinical pipeline.
Rachael Lester brings over 20 years of experience within the biopharmaceutical industry, having previously served as Chief Business Officer at Replicate Bioscience, where she played a significant role in corporate strategy and capital formation, securing key partnerships and financing during her tenure. Her background includes leading business development at Harpoon Therapeutics, where she established strategic partnerships with major players like AbbVie and Roche. With her extensive expertise, Lester is expected to elevate CytomX's capacity to forge valuable collaborations and optimize its integrated business model.
CytomX's current clinical pipeline includes promising candidates such as CX-2051, an antibody-drug conjugate targeting EpCAM, and CX-801, a masked interferon alpha-2b cytokine, both designed to address high unmet medical needs in cancer treatment. The company's mission is reinforced by its strategic collaborations with industry leaders, allowing it to leverage unique therapies aimed at improving patient outcomes in oncology.
In summary, Rachael Lester's appointment comes at a pivotal moment for CytomX, as the company seeks to maximize the potential of its innovative biologics in the fight against cancer.
MWN-AI** Analysis
CytomX Therapeutics (Nasdaq: CTMX) has made a strategic move by appointing Rachael Lester as Chief Business Officer, a decision that carries significant implications for both the company and its investors. With over two decades of experience in corporate strategy and business development within the biopharmaceutical industry, Lester brings a wealth of expertise that could enhance CytomX’s strategic trajectory. Her previous roles, particularly at Harpoon Therapeutics and Replicate Bioscience, highlight her ability to forge valuable partnerships and secure financing, skills that are essential for a company focused on innovation in oncology.
Investors should consider this appointment as a positive signal, particularly given the promising pipeline of CytomX's clinical assets, including CX-2051 and CX-801, aimed at addressing unmet medical needs in cancer treatment. The enhanced leadership team, now fortified by Lester's experience, could drive the execution of strategic initiatives necessary to advance these candidates through clinical stages and ultimately to market.
Moreover, Lester's mention of unlocking the potential of the PROBODY platform suggests that CytomX could pursue opportunities for broader applications in cancer treatment, amplifying its market presence. The company already has established collaborations with well-known oncology leaders such as Amgen and Bristol Myers Squibb, which further validates its innovative approach and could enhance its market reach.
However, potential investors should also weigh risks associated with biopharmaceutical investments, including regulatory hurdles and market competition. As CytomX focuses on unlocking its pipeline’s value, close monitoring of clinical trial outcomes and partnership developments will be essential. Overall, with its strategic leadership now strengthened, CytomX holds significant upside potential worth considering in a diversified biotech portfolio.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice President, Chief Business Officer. In this role, Ms. Lester will lead the Company’s strategy and business development functions.
“Rachael brings a wealth of experience in strategic planning and business development across the biopharmaceutical industry and joins CytomX at a time when our platform and pipeline are well positioned to deliver meaningful advances in the treatment of many cancers,” said Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics. “Rachael’s expertise and leadership in delivering strategic, value-enhancing partnerships will be pivotal as we continue to prosecute our integrated business model and expand the reach of our PROBODY ® platform. With her proven track record, Rachael strengthens our leadership team at a critical time for the Company. My colleagues and I look forward to working with Rachael in our collective mission to urgently advance innovative cancer therapies for patients.”
“I’m thrilled to join CytomX at such an exciting time. CytomX’s lead clinical assets, CX-2051 and CX-801, are designed to address areas of high unmet medical need including colorectal cancer and melanoma and have broad potential across many cancer types. I look forward to working with the highly dedicated team at CytomX to further unlock the value of the PROBODY ® platform and build on the promise of our pipeline of masked biologics.” said Ms. Lester.
Ms. Lester joins CytomX with over two decades leading corporate strategy, business development and product portfolio planning across the life science and biopharmaceutical industry. Most recently, she was Chief Business Officer at Replicate Bioscience, where she led corporate strategy, business development and capital formation. She was key in securing financing and multiple partnerships to transform the Company during her tenure. Prior to joining Replicate, Ms. Lester served as SVP of Business Development and Corporate Strategy at Harpoon Therapeutics, a novel T cell engager platform company that was later acquired by Merck, where she established and strengthened the business development strategy through major partnerships with AbbVie and Roche. Previously, Ms. Lester held senior roles in corporate strategy, portfolio management, and commercialization at Bruin Biometrics and Onyx Pharmaceuticals, now an Amgen subsidiary. Earlier in her career, she worked in Deloitte and Booz Allen Hamilton’s life sciences consulting practices, where she advised on multi-billion-dollar M&A transactions, new product planning and strategic growth initiatives. Ms. Lester received her M.B.A. from the Kellogg School of Management at Northwestern University and her B.A. in Neuroscience from University of Pennsylvania.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked biologics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY ® therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s multi-modality technology platform has produced therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. CytomX’s current clinical-stage pipeline includes CX-2051 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM), armed with a topoisomerase-1 inhibitor payload. CX-2051 has potential applicability across multiple EpCAM-expressing epithelial cancers, including CRC, and was discovered in collaboration with ImmunoGen. CX-801 is a masked interferon alpha-2b PROBODY ® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Redhouse Communications
Teri Dahlman
teri@redhousecomms.com
FAQ**
How can the appointment of Rachael Lester as Senior VP and Chief Business Officer of CytomX Therapeutics Inc. CTMX enhance the company's strategic partnerships and overall business development strategy?
What specific advancements in cancer treatment does CytomX Therapeutics Inc. CTMX aim to achieve with their lead clinical assets, CX-2051 and CX-801?
Given Rachael Lester's previous success in securing financing and partnerships, how does CytomX Therapeutics Inc. CTMX plan to leverage her expertise to accelerate their pipeline development?
What are the key milestones CytomX Therapeutics Inc. CTMX expects to reach with its PROBODY® platform in the near future, particularly regarding its collaborations with major oncology leaders?
**MWN-AI FAQ is based on asking OpenAI questions about CytomX Therapeutics Inc. (NASDAQ: CTMX).
NASDAQ: CTMX
CTMX Trading
31.76% G/L:
$6.16 Last:
38,852,753 Volume:
$6.92 Open:
